CVS HEALTH CorpCVS
CVS HEALTH Corp Financial Overview 2021–2025
Updated Jul 10, 2026CVS Health absorbed a staggering $5.7 billion goodwill impairment charge in FY2025, laying bare the severe financial toll of integrating its newly acquired healthcare delivery operations. Despite steady top-line expansion across its insurance and pharmacy segments, the company is battling compressed profitability driven by soaring Medicare utilization and billions in legal settlements.
The enterprise expanded its scale significantly as total revenue grew from $292.1 billion in FY2021 to $402.1 billion in FY2025. However, this top-line surge was repeatedly overshadowed by outsized operational and legal costs, including a 38.0% operating income plunge down to $8.5 billion in FY2024. By FY2025, the underlying business still generated $10.6 billion in operating cash flow, but recurring opioid litigation charges and the bankruptcy of its Omnicare long-term care unit heavily battered the bottom line. Reflecting these strained margins and a depressed earnings profile of $1.39 per share, the stock traded at an elevated 57.1x earnings multiple with a $100.9 billion market cap at the close of FY2025.
Recent Developments (Q4 2025 and Q1 2026)
CVS Health posted a profitability rebound in Q1 2026, with net income surging 65.9% to $2.96 billion and operating income rising 38.7% to $4.68 billion. Total revenue climbed 6.2% year-over-year to $100.4 billion, driven by an 11.0% revenue jump in the Health Services segment and an improved 84.6% Medical Benefit Ratio. The company bolstered its governance by electing former Elevance CFO John E. Gallina to the Board of Directors on March 19, 2026, followed by shareholder approval of the 2026 Incentive Compensation Plan.
Bulls argue the absence of prior-year one-time charges and sustained pharmacy drug mix demand point to stabilizing core operations. Conversely, bears note that at 62.5x earnings as of the May 6, 2026 reporting date, the stock appears richly valued relative to recent earnings performance.
What to watch: continued improvement in the Medical Benefit Ratio; strategic input from new board oversight
Rev
$402.07B
FY2025
NI
$1.77B
FY2025
EPS
$1.40
FY2025
OCF
$10.64B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
CVS HEALTH Corp 8-K Report, Executive Changes (May 18, 2026)
CVS Health Corporation (CVS) filed an 8-K report on May 18, 2026, detailing the outcomes of its 2026 Annual Meeting of Stockholders held on May 14, 2026. The primary focus of this filing is the shareholder approval of the new 2026 Incentive Compensation Plan (ICP), which will replace the existing 2017 plan for awards granted after May 14, 2026. This plan was overwhelmingly approved by stockholders, signaling confidence in the company's executive compensation strategy moving forward. In addition to the approval of the 2026 ICP, the filing confirms the re-election of all 13 nominated directors for one-year terms. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 and approved, on an advisory basis, the compensation of the company's named executive officers. A single stockholder proposal regarding the reduction of the threshold for stockholder action by written consent was not approved.
CVS HEALTH Corp 8-K Report, Financial Results (May 6, 2026)
CVS Health Corporation (CVS) has filed a Form 8-K on May 6, 2026, to report its financial results for the three months ended March 31, 2026. The key details of these results are provided in a press release, furnished as Exhibit 99.1 to this filing. This filing is primarily an informational update, alerting investors to the company's performance during the first quarter of 2026. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release for a comprehensive overview. Investors should review Exhibit 99.1 to understand the company's revenue, earnings, and any significant operational developments or guidance provided for the period. It's important to note that the information furnished in this 8-K is not considered "filed" for certain regulatory purposes, meaning it won't be automatically incorporated into other SEC filings unless explicitly referenced.
CVS HEALTH Corp 8-K Report, Executive Changes (Mar 19, 2026)
CVS Health Corporation (CVS) announced a significant addition to its Board of Directors with the election of John E. Gallina, effective March 19, 2026. Mr. Gallina brings extensive financial expertise, having served as the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc. (ELV) for over seven years. His nearly three-decade tenure at Elevance, coupled with prior experience in senior audit and accounting roles, positions him as a valuable asset to CVS Health's governance. Importantly for investors, Mr. Gallina has been appointed to the Board's Audit Committee and has been designated an "audit committee financial expert." This appointment underscores CVS Health's commitment to robust financial oversight and compliance. His compensation as a non-employee director will align with the company's existing practices for its independent board members.
CVS HEALTH Corp 8-K Report, Financial Results (Feb 10, 2026)
CVS Health Corporation filed an 8-K on February 10, 2026, to furnish a press release announcing its financial results for the three months and full year ended December 31, 2025. While the filing itself does not contain detailed financial figures, it directs investors to the press release (Exhibit 99.1) for this crucial information. The press release, therefore, is the primary source for understanding the company's recent performance and financial condition. Investors should carefully review the furnished press release to gain insights into key performance indicators, revenue growth, profitability, and any forward-looking statements or guidance provided by CVS Health. The 8-K filing serves as a formal notification and makes the press release publicly available, ensuring transparency regarding the company's financial reporting for the period ending December 31, 2025.
CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Dec 9, 2025)
CVS Health Corporation (CVS) filed an 8-K on December 8, 2025, to announce information presented at its 2025 Investor Day held on December 9, 2025. The key takeaway for investors is the company's issuance of an updated 2025 full-year financial outlook and the provision of its initial financial guidance for the 2026 full-year. This filing includes a press release (Exhibit 99.1) that details these financial projections and outlines the company's strategic priorities, offering investors a forward-looking perspective on CVS Health's performance and strategic direction. While the 8-K itself doesn't contain detailed financial statements, it directs investors to the furnished press release for critical updates. Investors should carefully review Exhibit 99.1 to understand the specific financial targets for both the remainder of 2025 and the upcoming 2026 fiscal year, as well as the strategic initiatives expected to drive these results. The company's disclosure aims to provide transparency and manage expectations regarding its financial trajectory and business plans.
View all 8-K filings →